$2.4 Billion Settlement Offered in Actos® Bladder Cancer Lawsuits

Actos® is a medication that has been used to treat diabetes in thousands of Americans. Unfortunately, studies have shown the drug is linked to an increased risk of the patient developing bladder cancer.

In 2011, the U.S. Food and Drug Administration required the company that manufactures the drug, Takeda Pharmaceuticals, to update the label of the product to include a warning to patients about the increased Actos® bladder cancer risk; however, it was already too late for many users who had already developed the disease.

Many of the patients who developed cancer as a result of using Actos® filed lawsuits against Takeda, claiming the company had kept the risks associated with the drug hidden from consumers. Several of the cases went to trial with mixed results. Just yesterday though, it was announced that Takeda Pharmaceuticals is offering to settle a majority of the roughly 9,000 pending lawsuits for a total of $2.4 billion.

The New York Times released an article stating Takeda was not found liable as part of the settlement and admitted no wrongdoing.

The settlement will only be finalized if 95 percent of the victims agree to its terms.

At the law firm of Fleschner, Stark, Tanoos & Newlin, we’ve seen the struggles the victims of Actos® bladder cancer have faced in their journey to justice. That’s why our Terre Haute personal injury lawyers hope the settlement brings a sense of closure to each of the victims who have suffered because of taking this particular drug.

Reach out to a Terre Haute Personal Injury Attorney Today

The financial burden that often comes with a serious injury can be too much for many people to bear. Unexpected medical debt, damaged personal property, and the sudden loss of income can impact the budgets of most families. The good news is that a successful injury claim could help reduce that financial strain after a serious accident. Get in touch with a Terre Haute personal injury lawyer with Fleschner, Stark, Tanoos & Newlin to learn more.

    *You agree to our Terms and Privacy Policy, and you are providing consent to receive communications including calls, emails, and texts.